| Fair Value Measurements |
Financial assets measured at fair value on a recurring basis are
summarized as follows, in thousands:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Description
|
|
At June 30, 2016 |
|
|
Quoted Prices in
Active Markets
(Level 1) |
|
|
Other Significant
Observable Inputs
(Level 2) |
|
|
Significant
Unobservable Inputs
(Level 3) |
|
|
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restricted cash
|
|
$ |
50 |
|
|
$ |
— |
|
|
$ |
50 |
|
|
$ |
— |
|
|
Cash equivalents
|
|
|
3,000 |
|
|
|
— |
|
|
|
3,000 |
|
|
|
— |
|
|
Short-term investments
|
|
|
2,000 |
|
|
|
— |
|
|
|
2,000 |
|
|
|
— |
|
|
Thera Warrant
|
|
|
5 |
|
|
|
— |
|
|
|
— |
|
|
|
5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$ |
5,055 |
|
|
$ |
— |
|
|
$ |
5,050 |
|
|
$ |
5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Description
|
|
At December 31, 2015 |
|
|
Quoted Prices in
Active Markets
(Level 1) |
|
|
Other Significant
Observable Inputs
(Level 2) |
|
|
Significant
Unobservable Inputs
(Level 3) |
|
|
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restricted cash
|
|
$ |
50 |
|
|
$ |
— |
|
|
$ |
50 |
|
|
$ |
— |
|
|
Cash equivalents
|
|
|
2,500 |
|
|
|
— |
|
|
|
2,500 |
|
|
|
— |
|
|
Short-term investments
|
|
|
5,500 |
|
|
|
— |
|
|
|
5,500 |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$ |
8,050 |
|
|
$ |
— |
|
|
$ |
8,050 |
|
|
$ |
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Financial assets measured at fair value on a recurring basis are
summarized as follows, in thousands:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Description
|
|
December 31, 2015 |
|
|
Quoted Prices
In Active Markets
(Level 1) |
|
|
Other Significant
Observable Inputs
(Level 2) |
|
|
Significant
Unobservable Inputs
(Level 3) |
|
|
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restricted cash
|
|
$ |
50 |
|
|
$ |
— |
|
|
$ |
50 |
|
|
$ |
— |
|
|
Cash equivalents
|
|
|
2,500 |
|
|
|
— |
|
|
|
2,500 |
|
|
|
— |
|
|
Short-term investments
|
|
|
5,500 |
|
|
|
— |
|
|
|
5,500 |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$ |
8,050 |
|
|
$ |
— |
|
|
$ |
8,050 |
|
|
$ |
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Description
|
|
December 31, 2014 |
|
|
Quoted Prices
In Active Markets
(Level 1) |
|
|
Other Significant
Observable Inputs
(Level 2) |
|
|
Significant
Unobservable Inputs
(Level 3) |
|
|
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restricted cash
|
|
$ |
50 |
|
|
$ |
— |
|
|
$ |
50 |
|
|
$ |
— |
|
|
Cash equivalents
|
|
|
4,000 |
|
|
|
— |
|
|
|
4,000 |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$ |
4,050 |
|
|
$ |
— |
|
|
$ |
4,050 |
|
|
$ |
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Additional Information about Assets Measured at Fair Value on a Recurring Basis |
The following table presents additional information about assets
measured at fair value on a recurring basis and for which the
Company utilizes Level 3 inputs to determine fair value, in
thousands:
|
|
|
|
|
|
|
|
|
| |
|
3 Months Ended
June 30, 2016 |
|
|
6 Months Ended
June 30, 2016 |
|
|
Balance, beginning of period
|
|
$ |
— |
|
|
$ |
— |
|
|
Fair value of Thera Warrant
|
|
|
5 |
|
|
|
5 |
|
|
|
|
|
|
|
|
|
|
|
Balance, end of period
|
|
$ |
5 |
|
|
$ |
5 |
|
|
|
|
|
|
|
|
|
|
|
|